Pricing: Free for Members, $99/Session for Non-Members

Wednesday, August 12, 2026

Program Description:

To participate in eLearning Day, you must register for each session individually by clicking the "Register" tab above and selecting the sessions you would like to attend.

11-11:45am ET

AI's Defining Question: Humans In, On, or Out of the Loop?

Artificial intelligence is rapidly transforming healthcare, but what does that mean for the future of patients, providers, and decision-makers? 

This pre-session teaser webinar introduces the central question behind an upcoming debate at AMCP Nexus: Will artificial intelligence lead us toward a more advanced healthcare system—or an “anti-human” future in medicine and healthcare? Through a balanced exploration of current trends, real-world applications, and emerging concerns, participants will gain a foundational understanding of both sides of this complex issue.

The session will highlight where AI is already influencing managed care pharmacy, raise key ethical and operational questions, and prepare attendees to actively engage in the live debate experience at Nexus. Join us to sharpen your perspective and be ready to take a stance. 

2-3pm ET

Building Trust in AI: Governance Strategies for Managed Care Pharmacy

Artificial intelligence is advancing rapidly across healthcare, but successful adoption requires more than new technology and it requires trust, governance, and clear oversight. As health plans, PBMs, and healthcare organizations evaluate AI-enabled solutions, leaders face critical questions about validation, transparency, accountability, and risk management. 

This session will explore how the Coalition for Health AI (CHAI) is helping establish industry frameworks for the responsible use of AI in healthcare. Participants will learn how healthcare organizations are approaching AI governance, what best practices are emerging for evaluating AI tools, and how managed care pharmacy leaders can prepare their organizations for safe and effective AI adoption.  

4-5pm ET

Reducing Nonadherence and Rehospitalization Through Effective Tardive Dyskinesia Treatment

Sponsored and presented by Real World CE LLC, separate registration required. Click here to register.

Supported by an educational grant from Teva Pharmaceuticals Industries Ltd.

This interactive, AI-enabled educational session, developed in conjunction with the National Organization for Tardive Dyskinesia, aims to describe the importance of adherence to monitoring recommendations, the use of validated assessment tools, the effectiveness of first-line treatments, and the importance of efficacious treatment in reducing total cost of care and rehospitalization risk created when TD is not treated according to updated guidelines.

Learning Objectives:

• Describe the physical, psychological, and socioeconomic impacts of TD symptoms along with the recommended monitoring guidelines for patients being treated with antipsychotics.
• Describe the use of clinical tools for the assessment of TD across recommended patient populations.
• Differentiate between guideline-recommended, FDA-approved first-line treatments and second-line options for TD based on the latest real-world evidence.
• Construct population health management strategies that balance the economic impact of VMAT-2 inhibitors with long-term patient outcomes and reductions in total healthcare resource utilization.

To Join Live Sessions:

• Join live sessions from your Pending Activities list by clicking the individual session name and then "Take Course." OR
• Click the "join session" link in the registration confirmation email; a separate email will be sent for each session you register for.